Experimental cell therapy offers hope for patients exhausting all treatment options
NCT ID NCT07122076
Summary
This early-stage study is testing the safety of an experimental cell therapy called GT719 injection in people with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle diseases that haven't improved with standard medications. The trial will enroll 10 participants to monitor for side effects and see if the treatment shows any early signs of helping control their disease. Researchers will track how the body handles the cells and look for changes in disease activity scores over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.